Surfix expands Supervisory Board with three seasoned industry leaders

Surfix is delighted to welcome three new members to our board of directors: Artur Aira, Bob van Gemen and Michael Stocum, three accomplished industry experts. With their combined experience in the biotechnology, diagnostic and life science industries of more than 75 years, the board has gained a wealth of knowledge and experience to help direct Surfix to success.

Artur Aira describes himself as a passionate leader and entrepreneur with over 25 years of CEO and leadership experience within the life science industry internationally. With his experience with acquisitions, boards, start-ups, founded and developed fast growing companies, as well as his technical and sales background, he is a great asset as the new chair of our board.

Bob van Gemen brings in extensive knowledge in medical devices, biotechnology, R&D, life sciences, and technology transfer, with a demonstrated history of working in the biotechnology and CRO industry for over 30 years.

Similarly, Michael Stocum, a serial entrepreneur, has over 30 years of experience leading innovative business initiatives across the pharmaceutical, biotechnology and clinical diagnostic laboratory industries. Mike has a focus on creating a strategic vision, aligning funding with business planning and partnerships to operationally deliver value-added product development and commercial success.

The new board was installed on October 28, 2024.

Surfix is redefining point-of-care diagnostics with an innovative Photonic Diagnostic Platform; a multi-modal solution that combines superior precision for protein detection over current lab-testing platforms with the speed and simplicity of point-of-care testing. As a rapidly growing startup, our focus is on strategic partnerships for co-developing immunoassays with diagnostic, biomarker discovery, and biopharmaceutical companies and then expanding our platform to include molecular and combined capabilities.